Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 1
- 17. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
Cited by
Items 101–200 of 1,000
Cristóbal, I., Blanco, F. J., Garcia-Orti, L., Marcotegui, N., Vicente, C., Rifon, J., Novo, F. J., Bandres, E., Calasanz, M. J., Bernabeu, C., et al. (2010) · Blood · doi:10.1182/blood-2009-06-227363 · Cited by 173
Mills, K. I., Kohlmann, A., Williams, P. M., Wieczorek, L., Liu, W.-M., Li, R., Wei, W., Bowen, D. T., Loeffler, H., Hernandez, J. M., et al. (2009) · Blood · doi:10.1182/blood-2008-10-187203 · Cited by 167
“Less than 5% 114 (70) 92 (66) 72 (65) 5%-10% 29 (18) 26 (19) 20 (18) 11%-20% 21 (13) 21 ( 15 ) 18 (16)”
InfluentialCancer gene expression signatures – The rise and fall?
Chibon, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.021 · Cited by 164
Chronotherapy and the molecular clock: Clinical implications in oncology☆
Innominato, P. F., Lévi, F. A., & Bjarnason, G. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.06.002 · Cited by 164
Lavallée, V.-P., Baccelli, I., Krosl, J., Wilhelm, B., Barabé, F., Gendron, P., Boucher, G., Lemieux, S., Marinier, A., Meloche, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3371 · Cited by 172
Li, Z., Huang, H., Chen, P., He, M., Li, Y., Arnovitz, S., Jiang, X., He, C., Hyjek, E., Zhang, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms1681 · Cited by 164
Self-citationTaube, F., Georgi, J. A., Kramer, M., Stasik, S., Middeke, J. M., Röllig, C., Krug, U., Krämer, A., Scholl, S., Hochhaus, A., et al. (2022) · Blood · doi:10.1182/blood.2020009680 · Cited by 162
Self-citationLeukemogenic transformation by HOXA cluster genes
Bach, C., Buhl, S., Mueller, D., García-Cuéllar, M.-P., Maethner, E., & Slany, R. K. (2010) · Blood · doi:10.1182/blood-2009-04-216606 · Cited by 159
Baldus, C. D., Thiede, C., Soucek, S., Bloomfield, C. D., Thiel, E., & Ehninger, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6253 · Cited by 163
de Rooij, J. D. E., Hollink, I. H. I. M., Arentsen-Peters, S. T. C. J. M., van Galen, J. F., Beverloo, H. B., Baruchel, A., Trka, J., Reinhardt, D., Sonneveld, E., Zimmermann, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.87 · Cited by 163
Self-citationRubnitz, J. E., Gibson, B., & Smith, F. O. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.008 · Cited by 158
Wang, K., Wang, P., Shi, J., Zhu, X., He, M., Jia, X., Yang, X., Qiu, F., Jin, W., Qian, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.045 · Cited by 162
The human immune response to tuberculosis and its treatment: a view from the blood
Cliff, J. M., Kaufmann, S. H. E., McShane, H., van Helden, P., & O'Garra, A. (2015) · Immunological Reviews · doi:10.1111/imr.12269 · Cited by 159
Al-Matary, Y. S., Botezatu, L., Opalka, B., Hones, J. M., Lams, R. F., Thivakaran, A., Schutte, J., Koster, R., Lennartz, K., Schroeder, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.143180 · Cited by 155
“AML was confirmed based on cytological and flow cytometry examination.(22,27)”
MethodGene Microarray Analysis of Peripheral Blood Cells in Pulmonary Arterial Hypertension
Bull, T. M., Coldren, C. D., Moore, M., Sotto-Santiago, S. M., Pham, D. V., Nana-Sinkam, S. P., Voelkel, N. F., & Geraci, M. W. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1686oc · Cited by 161
Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Bernt, K. M., & Hunger, S. P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00054 · Cited by 169
The proteogenomic subtypes of acute myeloid leukemia
Jayavelu, A. K., Wolf, S., Buettner, F., Alexe, G., Häupl, B., Comoglio, F., Schneider, C., Doebele, C., Fuhrmann, D. C., Wagner, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.006 · Cited by 172
Quantitative DNA methylation predicts survival in adult acute myeloid leukemia
Bullinger, L., Ehrich, M., Döhner, K., Schlenk, R. F., Döhner, H., Nelson, M. R., & van den Boom, D. (2010) · Blood · doi:10.1182/blood-2009-03-211003 · Cited by 152
Vadakekolathu, J., Lai, C., Reeder, S., Church, S. E., Hood, T., Lourdusamy, A., Rettig, M. P., Aldoss, I., Advani, A. S., Godwin, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002512 · Cited by 154
Self-citationHorwitz, P. A., Tsai, E. J., Putt, M., Gilmore, J. M., Lepore, J. J., Parmacek, M. S., Kao, A. C., Desai, S., Goldberg, L. R., Brozena, S. C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000150539.72783.bf · Cited by 166
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
German, N. J., Yoon, H., Yusuf, R. Z., Murphy, J. P., Finley, L. W. S., Laurent, G., Haas, W., Satterstrom, F. K., Guarnerio, J., Zaganjor, E., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.014 · Cited by 156
Rapin, N., Bagger, F. O., Jendholm, J., Mora-Jensen, H., Krogh, A., Kohlmann, A., Thiede, C., Borregaard, N., Bullinger, L., Winther, O., et al. (2014) · Blood · doi:10.1182/blood-2013-02-485771 · Cited by 159
Deregulation of apoptosis in acute myeloid leukemia
Testa, U., & Riccioni, R. (2007) · Haematologica · doi:10.3324/haematol.10279 · Cited by 171
Tamayo, P., Scanfeld, D., Ebert, B. L., Gillette, M. A., Roberts, C. W. M., & Mesirov, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701068104 · Cited by 153
Langer, C., Marcucci, G., Holland, K. B., Radmacher, M. D., Maharry, K. S., Paschka, P., Whitman, S. P., Mrózek, K., Baldus, C. D., Vij, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6110 · Cited by 178
“0 GeneChips (Affymetrix, Santa Clara, CA), as previously reported (Appendix).(10,31) Of the 75 samples analyzed for genome-wide gene expression, 73 were also analyzed for genome-wide microRNA expression.”
MethodThangaraj, S. V., Shyamsundar, V., Krishnamurthy, A., Ramani, P., Ganesan, K., Muthuswami, M., & Ramshankar, V. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156582 · Cited by 163
“[6, 7] These high throughput studies have offered the advantage of understanding the biology of a cancer through an exhaustive analysis.”
BackgroundHOX expression patterns identify a common signature for favorable AML
Andreeff, M., Ruvolo, V, Gadgil, S., Zeng, C., Coombes, K., Chen, W., Kornblau, S., Barón, A. E., & Drabkin, H. A. (2008) · Leukemia · doi:10.1038/leu.2008.198 · Cited by 149
Kotini, A. G., Chang, C.-J., Chow, A., Yuan, H., Ho, T., Wang, T., Vora, S., Solovyov, A., Husser, C., Olszewska, M., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.01.009 · Cited by 163
“(E) GSEA of MDS/AML-iPSC-CD34+ cells compared to normal iPSC-CD34+ cells shows negative enrichment for the human AML Valk cluster 10 patient gene set (group with worse prognosis and chr7q abnormalities) (Valk et al., 2004).”
BackgroundCbfβ-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia
Kuo, Y., Landrette, S. F., Heilman, S. A., Perrat, P. N., Garrett, L. J., Liu, P. P., Beau, M. M. L., Kogan, S. C., & Castilla, L. H. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.014 · Cited by 159
Polycomb repressive complex 2 contributes to DNA double-strand break repair
Campbell, S., Ismail, I. H., Young, L. C., Poirier, G. G., & Hendzel, M. J. (2013) · Cell Cycle · doi:10.4161/cc.25795 · Cited by 144
“Furthermore, miR-31 overexpression resulted in downregulation of EZH2 and a de-repression of its target gene rap1GAP; increased expression of EZH2 was associated with melanoma progression and overall patient survival.(42) Since PcG are linked to malignant transformation in various hematological and epithelial cancers,…”
BackgroundPotential roles for the PIM1 kinase in human cancer – A molecular and therapeutic appraisal
Shah, N. H., Pang, B., Yeoh, K. G., Thorn, S., Chen, C. S., Lilly, M. B., & Salto‐Tellez, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.044 · Cited by 158
Deregulation of Signaling Pathways in Acute Myeloid Leukemia
Scholl, C., Gilliland, D. G., & Fröhling, S. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.004 · Cited by 163
Heuser, M., Argiropoulos, B., Kuchenbauer, F., Yung, E., Piper, J., Fung, S., Schlenk, R. F., Dohner, K., Hinrichsen, T., Rudolph, C., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080523 · Cited by 148
“Our data suggest that MN1 has at least 2 functions: (1) to promote self-renewal and proliferation; and (2) to block differentiation.”
BackgroundRapino, F., Robles, E. F., Richter-Larrea, J. A., Kallin, E. M., Martinez-Climent, J. A., & Graf, T. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.003 · Cited by 143
“Most recently, it was shown that cancer stem cells of acute myeloid leukemia (AML) can be selectively induced to differentiate using a drug that blocks dopamine receptors, strongly inhibiting tumor formation in a xenograft mouse model (Sachlos et al., 2012).”
InfluentialEvi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins
Yoshimi, A., Goyama, S., Watanabe-Okochi, N., Yoshiki, Y., Nannya, Y., Nitta, E., Arai, S., Sato, T., Shimabe, M., Nakagawa, M., et al. (2011) · Blood · doi:10.1182/blood-2009-12-261602 · Cited by 146
Epigenetic Modification of CCAAT/Enhancer Binding Protein α Expression in Acute Myeloid Leukemia
Hackanson, B., Bennett, K. L., Brena, R. M., Jiang, J., Claus, R., Chen, S.-S., Blagitko-Dorfs, N., Maharry, K., Whitman, S. P., Schmittgen, T. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0483 · Cited by 140
Transcriptional Profiling of Peripheral Blood Cells in Clinical Pharmacogenomic Studies
Burczynski, M. E., & Dorner, A. J. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.2.187 · Cited by 143
“Outcome prediction in the context of immunotherapy of neurodegenerative disease O’Toole and colleagues evaluated PBMC profiles in individuals with mild to moderate Alzheimer’s disease prior to therapy with AN1792 (Aβ[1-42]) in a study to evaluate safety, tolerability and pilot efficacy of this drug [60].”
BackgroundMethodGlass, J. L., Hassane, D., Wouters, B. J., Kunimoto, H., Avellino, R., Garrett-Bakelman, F. E., Guryanova, O. A., Bowman, R., Redlich, S., Intlekofer, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1032 · Cited by 142
“The AML patient samples analyzed in this study were collected at Erasmus University Medical Center (Rotterdam, The Netherlands) from 1990-2008 and processed as previously described (31, 32).”
MethodSelf-citationPitarch, A., Jiménez, A., Nombela, C., & Gil, C. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500243-mcp200 · Cited by 141
Mrózek, K., & Bloomfield, C. D. (2006) · Hematology · doi:10.1182/asheducation-2006.1.169 · Cited by 141
Translational implications of somatic genomics in acute myeloid leukaemia
Meyer, S. C., & Levine, R. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70008-7 · Cited by 149
Wang, Q.-F., Wu, G., Mi, S., He, F., Wu, J., Dong, J., Luo, R. T., Mattison, R., Kaberlein, J. J., Prabhakar, S., et al. (2011) · Blood · doi:10.1182/blood-2010-12-324699 · Cited by 132
Integrative analysis of RUNX1 downstream pathways and target genes
Michaud, J., Simpson, K. M., Escher, R., Buchet-Poyau, K., Beissbarth, T., Carmichael, C., Ritchie, M. E., Schütz, F., Cannon, P., Liu, M., et al. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-363 · Cited by 136
“For the correlation with clinical AML samples, the test dataset was the previously published expression profiling data on 285 AML patients and 8 healthy individuals [23].”
MethodResultInfluentialPayton, J. E., Grieselhuber, N. R., Chang, L.-W., Murakami, M., Geiss, G. K., Link, D. C., Nagarajan, R., Watson, M. A., & Ley, T. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38248 · Cited by 136
Applying Nanotechnology to Human Health: Revolution in Biomedical Sciences
Shrivastava, S., & Dash, D. (2009) · Journal of Nanotechnology · doi:10.1155/2009/184702 · Cited by 152
“Similar chips are being developed for the diagnosis of leukaemias [25, 26] and mouth and throat tumours [27].”
BackgroundLi, L., Piloto, O., Nguyen, H. B., Greenberg, K., Takamiya, K., Racke, F., Huso, D., & Small, D. (2008) · Blood · doi:10.1182/blood-2007-08-109942 · Cited by 130
Takeda, A., Goolsby, C. L., & Yaseen, N. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0458 · Cited by 142
Gadd45 Stress Sensors in Malignancy and Leukemia
Liebermann, D. A., Tront, J. S., Sha, X., Mukherjee, K., Mohamed-Hadley, A. A., & Hoffman‐Liebermann, B. (2011) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v16.i1-2.120 · Cited by 144
Signatures of cardioembolic and large‐vessel ischemic stroke
Jickling, G. C., Xu, H., Stamova, B., Ander, B. P., Zhan, X., Tian, Y., Liu, D., Turner, R. J., Mesias, M., Verro, P., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22187 · Cited by 129
Marcucci, G., Mrózek, K., & Bloomfield, C. D. (2004) · Current Opinion in Hematology · doi:10.1097/01.moh.0000149608.29685.d1 · Cited by 131
Genomic approaches to hematologic malignancies
Ebert, B. L., & Golub, T. R. (2004) · Blood · doi:10.1182/blood-2004-01-0274 · Cited by 131
Hackl, H., Astanina, K., & Wieser, R. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0416-0 · Cited by 142
Cahan, P., Rovegno, F., Mooney, D. L., Newman, J. C., Laurent, G. S., & McCaffrey, T. A. (2007) · Gene · doi:10.1016/j.gene.2007.06.016 · Cited by 129
“…al., 2002; Ramalho-Santos et al., 2002; Fortunel et al., 2003), alcohol consumption (Mulligan et al., 2006), cardiovascular disease (McCaffrey et al., 2000; Gagarin et al., 2005), cancer (Bullinger et al., 2004; Valk et al., 2004), inflammation (Calvano et al., 2005), and aging (Lu et al., 2004).”
BackgroundBouwens, M., Afman, L. A., & Müller, M. M. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1515 · Cited by 147
Camós, M., Esteve, J., Jares, P., Colomer, D., Rozman, M., Villamor, N., Costa, D., Carrió, A., Nomdedéu, J., Montserrat, E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4601 · Cited by 125
McWeeney, S. K., Pemberton, L. C., Loriaux, M., Vartanian, K. A., Willis, S. G., Yochum, G. S., Wilmot, B., Turpaz, Y., Pillai, R., Druker, B. J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210732 · Cited by 128
Kittleson, M. M., Ye, S. Q., Irizarry, R. A., Minhas, K. M., Edness, G., Conte, J. V., Parmigiani, G., Miller, L. W., Chen, Y., Hall, J. L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148178.19465.11 · Cited by 127
Guibal, F. C., Alberich-Jorda, M., Hirai, H., Ebralidze, A., Levantini, E., Di Ruscio, A., Zhang, P., Santana-Lemos, B. A., Neuberg, D., Wagers, A. J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182071 · Cited by 126
Ptasinska, A., Assi, S. A., Martinez-Soria, N., Imperato, M. R., Piper, J., Cauchy, P., Pickin, A., James, S. R., Hoogenkamp, M., Williamson, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.024 · Cited by 135
“Acute myeloid leukemia (AML) is the second most common leukemia and is a heterogeneous disease with impaired myeloid differentiation (Valk et al., 2004).”
Ročková, V., Abbas, S., Wouters, B. J., Erpelinck-Verschueren, C. A. J., Beverloo, H. B., Delwel, R., van Putten, W. L. J., Löwenberg, B., & Valk, P. J. M. (2011) · Blood · doi:10.1182/blood-2011-02-334748 · Cited by 123
Self-citationMohr, S., Doebele, C., Comoglio, F., Berg, T., Beck, J., Bohnenberger, H., Alexe, G., Corso, J., Ströbel, P., Wachter, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.001 · Cited by 127
“Subsets of AML with favorable genetic features, such as core-binding factor leukemias and PML-RARa-positive leukemias, express low levels of Hox genes (Drabkin et al., 2002; Lawrence et al., 1999; Valk et al., 2004).”
Bullinger, L., Rücker, F. G., Kurz, S., Du, J., Scholl, C., Sander, S., Corbacioglu, A., Lottaz, C., Krauter, J., Fröhling, S., et al. (2007) · Blood · doi:10.1182/blood-2006-10-049783 · Cited by 128
“Median in inv(16), 109/L (range) 47 (2-157) 29 ( 2-137 ) .057”
InfluentialRadmacher, M. D. (2006) · Blood · doi:10.1182/blood-2006-02-005538 · Cited by 122
“Age, y, median (range) 45 (24-59) 41 (21-59) .”
InfluentialTrib1 links the MEK1/ERK pathway in myeloid leukemogenesis
Yokoyama, T., Kanno, Y., Yamazaki, Y., Takahara, T., Miyata, S., & Nakamura, T. (2010) · Blood · doi:10.1182/blood-2009-10-246264 · Cited by 136
Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer
Candido, S., Maestro, R., Polesel, J., Catania, A., Maira, F., Signorelli, S. S., McCubrey, J. A., & Libra, M. (2014) · Oncotarget · doi:10.18632/oncotarget.1738 · Cited by 134
“00E-03 Valk PJ [110] 2004 U133A CLL 448 74 -42.”
MethodParascandolo, A., & Laukkanen, M. O. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7268 · Cited by 116
Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety
Löwenberg, B. (2008) · Hematology · doi:10.1182/asheducation-2008.1.1 · Cited by 118
“Likewise, AML genotypes with mutations in CCAAT/enhancer binding protein alpha (CEBPA), and mutations in nucleophosmin 1 (NPM1) show distinctive gene expression signatures.(6,42) The apparent fact that the genetic abnormality places such a prominent stamp on the transcriptome of the leukemia has important implications.”
BackgroundSelf-citationSox4 Is a Key Oncogenic Target in C/EBPα Mutant Acute Myeloid Leukemia
Zhang, H., Alberich-Jorda, M., Amabile, G., Yang, H., Staber, P. B., Di Ruscio, A., Welner, R. S., Ebralidze, A., Zhang, J., Levantini, E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.018 · Cited by 118
“However, among 16 groups of AML patients classified on the basis of molecular signatures (Valk et al., 2004), SOX4 is only upregulated in AML subtypes carrying bi-allelic mutated and silent CEBPA , or internal tandem duplication mutation of FLT3 (FLT3-ITD).”
InfluentialSelf-citationPrognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use
Liersch, R., Müller‐Tidow, C., Berdel, W. E., & Krug, U. O. (2014) · British Journal of Haematology · doi:10.1111/bjh.12750 · Cited by 140
“Global gene expression profiles could identify prognostic groups within different cytogenetic risk groups (Bullinger et al, 2004; Valk et al, 2004).”
BackgroundComparative and integrative functional genomics of HCC
Lee, J.-S., & Thorgeirsson, S. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209561 · Cited by 121
“…clinical phenotype and discovering subtypes of cancers previously unidentified Oncogene with conventional technologies (Alizadeh et al., 2000; van de Vijver et al., 2002; Bullinger et al., 2004; Dave et al., 2004; Lapointe et al., 2004; Valk et al., 2004; Lee et al., 2004a; Roepman et al., 2005).”
BackgroundMethodGene Expression Profiling in Acute Myeloid Leukemia
Bullinger, L., & Valk, P. J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.020 · Cited by 115
Self-citationEffect of separate sampling on classification accuracy
Esfahani, M. S., & Dougherty, E. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt662 · Cited by 115
“The results for the dataset [16] are given in the article.”
InfluentialAlves, R. D. A. M., Eijken, M., van de Peppel, J., & van Leeuwen, J. P. T. M. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-965 · Cited by 114
“Genes underlying these GO-terms were subsequently used for correlation analysis essentially as described elsewhere [28,53].”
MethodHarnessing the immune system in acute myeloid leukaemia
Austin, R. J., Smyth, M. J., & Lane, S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.020 · Cited by 120
“Patients with distinct genetic abnormalities have distinct gene expression and epigenetic profiles [50-52].”
Smith, L., Yeung, J., Zeisig, B. B., Popov, N., Huijbers, I. J., Barnes, J. L., Wilson, A. J., Taskesen, E., Delwel, R., Gil, J., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.05.004 · Cited by 124
“…may influence Bmi1 dependency, we compared the expression profiles of 84 AML patients carrying specific genetic abnormalities including AE (n = 38), RARa fusions (n = 30 including 26 PML-RARa and 4 PLZF-RARa), and MLL fusions (n = 16) (Rice et al., 2009; Valk et al., 2004; Verhaak et al., 2009).”
BackgroundSelf-citationAberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1
Lugthart, S., Figueroa, M. E., Bindels, E. M., Skrabanek, L. A., Valk, P. J. M., Li, Y., Meyer, S., Erpelinck-Verschueren, C. A. J., Greally, J. M., Löwenberg, B., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281337 · Cited by 119
Self-citationIncreasing recognition of the importance of aldehyde oxidase in drug development and discovery
Garattini, E., & Terao, M. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.560606 · Cited by 111
Bouwens, M., Bromhaar, M. G., Jansen, J., Müller, M. M., & Afman, L. A. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28586 · Cited by 125
Prognostic Cancer Gene Expression Signatures: Current Status and Challenges
Qian, Y., Daza, J., Itzel, T., Betge, J., Zhan, T., Marmé, F., & Teufel, A. (2021) · Cells · doi:10.3390/cells10030648 · Cited by 131
Balgobind, B. V., van den Heuvel‐Eibrink, M. M., Menezes, R. X. D., Reinhardt, D., Hollink, I. H. I. M., Arentsen-Peters, S. T. C. J. M., van Wering, E. R., Kaspers, G. J. L., Cloos, J. J., de Bont, E. S. J. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.029660 · Cited by 124
Self-citationErdem-Eraslan, L., Gravendeel, L. A., de Rooi, J., Eilers, P. H. C., Idbaih, A., Spliet, W. G. M., den Dunnen, W. F. A., Teepen, J. L., Wesseling, P., Sillevis Smitt, P. A. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1444 · Cited by 109
Shi, J., Fu, H., Jia, Z., He, K., Fu, L. N., & Wang, W. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.025 · Cited by 116
“, 2008), GSE1159 (Valk et al., 2004), GSE9476 (Stirewalt et al.”
Pasqualucci, L., Liso, A., Martelli, M. P., Bolli, N., Pacini, R., Tabarrini, A., Carini, M., Bigerna, B., Pucciarini, A., Mannucci, R., et al. (2006) · Blood · doi:10.1182/blood-2006-06-026716 · Cited by 110
Coenen, E. A., Zwaan, C. M., Reinhardt, D., Harrison, C. J., Haas, O. A., de Haas, V., Mihál, V., Moerloose, B. D., Jeison, M., Rubnitz, J. E., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485524 · Cited by 113
Fang, J., Rhyasen, G., Bolanos, L., Rasch, C., Varney, M., Wunderlich, M., Goyama, S., Jansen, G., Cloos, J., Rigolino, C., et al. (2012) · Blood · doi:10.1182/blood-2012-02-407999 · Cited by 105
Docking, R., Parker, J., Jädersten, M., Duns, G., Chang, L., Jiang, J., Pilsworth, J. A., Swanson, L., Chan, S. K., Chiu, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22625-y · Cited by 121
“Among the most downregulated genes, we observed TRH (previously described as being associated with t(8;21) AML)46, IL5RA, and the heme peroxidases LPO and MPO.”
BackgroundAurelius, J., Thorén, F. B., Akhiani, A. A., Brune, M. L., Palmqvist, L., Hansson, M., Hellstrand, K., & Martner, A. (2012) · Blood · doi:10.1182/blood-2011-11-391722 · Cited by 113
Zeng, Z., Samudio, I. J., Zhang, W., Estrov, Z. E., Pelicano, H., Harris, D., Frolova, O., Hail, N., Chen, W., Kornblau, S. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1278 · Cited by 115
Gönen, M., Sun, Z., Figueroa, M. E., Patel, J. P., Abdel-Wahab, O. I., Racevskis, J., Ketterling, R. P., Fernandez, H. F., Rowe, J. M., Tallman, M. S., et al. (2012) · Blood · doi:10.1182/blood-2012-02-414425 · Cited by 108
Haferlach, T., Kohlmann, A., Klein, H.-U., Ruckert, C., Dugas, M., Williams, P. M., Kern, W., Schnittger, S., Bacher, U., Löffler, H., et al. (2009) · Leukemia · doi:10.1038/leu.2008.388 · Cited by 112
de Jonge, H. J. M., Valk, P. J. M., Veeger, N. J. G. M., ter Elst, A., den Boer, M. L., Cloos, J. J., de Haas, V., van den Heuvel‐Eibrink, M. M., Kaspers, G. J. L., Zwaan, C. M., et al. (2010) · Blood · doi:10.1182/blood-2010-03-270991 · Cited by 108
Self-citationReikvam, H., Hatfield, K. J., Kittang, A. O., Hovland, R., & Bruserud, Ø. (2011) · BioMed Research International · doi:10.1155/2011/104631 · Cited by 112
“Global gene expression profiling in AML has revealed that major prognostic subgroups based on genetic markers are recapitulated in large-scale gene expression patterns [4, 155, 156].”
BackgroundInfluentialThe molecular characterization and clinical management of multiple myeloma in the post-genome era
Zhou, Y., Barlogie, B., & Shaughnessy, J. D. (2009) · Leukemia · doi:10.1038/leu.2009.160 · Cited by 104
Schwarz, E., van Beveren, N. J. M., Ramsey, J., Leweke, F. M., Rothermundt, M., Bogerts, B., Steiner, J., Guest, P. C., & Bahn, S. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt105 · Cited by 105
Paschka, P., Schlenk, R. F., Weber, D., Benner, A., Bullinger, L., Heuser, M., Gaidzik, V. I., Thol, F. R., Agrawal, M., Teleanu, V., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0129-6 · Cited by 107
RARAfusion genes in acute promyelocytic leukemia: a review
Braekeleer, E. D., Douet‐Guilbert, N., & Braekeleer, M. D. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.903794 · Cited by 116
“However, although no comparative gene expression profiling has been performed between PML–RARA and ZBTB16–RARA samples, available data appear to show differences in their expression signature [123–127].”
BackgroundTranscriptional dysregulation during myeloid transformation in AML
Pabst, T., & Mueller, B. U. (2007) · Oncogene · doi:10.1038/sj.onc.1210765 · Cited by 120
“Using microarray analysis, AML patients with nonsilent CEBPA mutations express a distinctive gene expression signature (Bullinger et al., 2004; Valk et al., 2004; Keeshan et al., 2006).”
BackgroundResultInfluentialGe, Y., Dombkowski, A. A., LaFiura, K. M., Tatman, D., Yedidi, R. S., Stout, M. L., Buck, S. A., Massey, G. V., Becton, D. L., Weinstein, H. J., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2219 · Cited by 110
Andersson, A., Olofsson, T., Lindgren, D., Nilsson, B., Ritz, C., Edén, P., Lassen, C., Råde, J., Fontes, M., Mörse, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506637102 · Cited by 108
Chamuleau, M. E. D., van de Loosdrecht, A. A., Hess, C. J., Janssen, J. J. W. M., Zevenbergen, A., Delwel, R., Valk, P. J. M., Löwenberg, B., & Ossenkoppele, G. J. (2008) · Haematologica · doi:10.3324/haematol.13113 · Cited by 115
Self-citation
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.